预约演示
更新于：2025-08-22
Iopromide
碘普罗胺
更新于：2025-08-22
概要
基本信息
药物类型 造影剂、小分子化药 |
别名 Iopromide (JAN/USP/INN)、N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamide、碘普胺 + [7] |
作用方式 拮抗剂、增强剂 |
作用机制 M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂)、射线照相增强剂 |
非在研适应症- |
原研机构- |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (1991-09-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24I3N3O8 |
InChIKeyDGAIEPBNLOQYER-UHFFFAOYSA-N |
CAS号73334-07-3 |
关联
15
项与 碘普罗胺 相关的临床试验NCT03631771
A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.
NCT04605471
Safety Profile of Ultravist in Children and Elderly (UV Age)
NCT03622801
Risk of Anaphylactoid Reactions of Iopromide After Intra-arterial Administration
100 项与 碘普罗胺 相关的临床结果
登录后查看更多信息
100 项与 碘普罗胺 相关的转化医学
登录后查看更多信息
100 项与 碘普罗胺 相关的专利（医药）
登录后查看更多信息
1,443
项与 碘普罗胺 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Simultaneous determination of three iodinated contrast media in human plasma by LC/MS-MS and its clinical application
Article
作者: Wu, Xiaofei ; Wang, Hongyun ; Wang, Yaoyao ; Cai, Jianfang ; Liu, Shupeng
Iodinated contrast media (ICM), including iohexol, iopromide and iodixanol, have significantly enhanced diagnostic accuracy, particularly in cardiovascular and cerebrovascular diseases. The three ICM is tailored to specific patient needs and diagnostic contexts. However, excessive doses of ICM may induce adverse reactions, including nephrotoxicity. Accurate measurement of ICM concentration is essential for reducing renal burden and ensuring patient safety. Current methods for quantifying ICM are often limited to single-analyte detection (especially iohexol), which is inefficient for clinical practice. Therefore, this method aims to develop and validate a rapid, generic LC-MS/MS method for simultaneously quantifying iohexol, iopromide, and iodixanol in human plasma to improve patient management and prognosis. An LC-MS/MS-based approach was established utilizing an C18 column coupled with a Xevo TQ-S triple quadrupole mass spectrometer. Sample preparation involved protein precipitation, while chromatographic separation was achieved using acetonitrile and 0.1 % formic acid in water. The developed LC-MS/MS method achieved satisfactory separation of the three ICM within 1.5 min. Calibration curves for iohexol, iopromide, and iodixanol showed good linearity in 5.00-5000, 5.00-5000 and 10.0 ∼ 10000 µg/mL, respectively. The method was effectively applied to analyze 71 plasma samples from 9 patients, highlighting its clinical utility. A rapid and generic LC-MS/MS method streamlines sample preparation and standardizes laboratory workflows, making it suitable for clinical bio-samples.
2025-08-14Allergy, Asthma and Clinical Immunology
The role of skin testing, drug challenge and IFN-γ ELISpot in delayed hypersensitivity to iodinated contrast media.
Article
作者: Chua, Kyra Y L ; Lee, Derek ; AlGassim, Moneerah ; Phillips, Elizabeth J ; Ben-Shoshan, Moshe ; Stehlin, Florian ; Mouhtouris, Effie ; Al Otaibi, Ibtihal ; Tsoukas, Christos ; Trubiano, Jason A ; Toupin, Jean-Francois ; Holmes, Natasha E ; Isabwe, Ghislaine A C ; Copaescu, Ana Maria
BACKGROUND:
The use of in vivo and ex vivo diagnostic tools for delayed hypersensitivity reactions (DHRs) associated with iodinated contrast media (ICM) is currently ill-defined.
OBJECTIVE:
To evaluate the role of in vivo and ex vivo diagnostic tools for DHRs occurring >6 h following intravenous low-osmolality ICM.
METHODS:
We conducted a prospective, multicenter, international cohort study. The patients were recruited from two tertiary care adult allergy clinics, Austin Health, Australia and the McGill University Health Centre, Canada. Eligible participants were adults who reported a DHR after receiving ICM. In vivo testing (skin testing and intravenous challenge) was performed to identify an alternative agent. Ex vivo testing using interferon-γ enzyme-linked ImmunoSpot assay was performed in four Australian patients to explore its diagnostic performance.
RESULTS:
The culprit ICM was identified by dIDT in 17/20 (85%) while in 3/20 (15%) a challenge was necessary to confirm delayed hypersensitivity. All patients with a positive dIDT to iohexol were positive to iodixanol (15/15; 100%) while 3/4 (75%), 3/4 (75%), 4/6 (67%), and 3/5 (60%) were positive to iopromide, ioversol, iopamidol, and iobitridol, respectively. Overall, 7/20 (35%) patients tolerated a challenge with an alternative ICM. The IFN-γ release assay was negative for the implicated ICM in 4 patients with confirmed DHR through a positive dIDT.
CONCLUSION:
dIDT allowed confirmation of T cell-mediated allergy to the implicated ICM in 85% of patients with a strong clinical suspicion of DHR and identification of non-cross-reactive ICM in 35% of patients. The IFN-y ELISpot was not useful in the four patients tested.
2025-08-01JOURNAL OF HAZARDOUS MATERIALS
Evaluation of micropollutant removal from artificially recharged water using activated carbon
Article
作者: Šváb, Marek ; Vorokhta, Maryna ; Švábová, Martina ; Pohořelý, Michael
Pilot scale micropollutant removal onto three types of granular activated carbon was tested over a period of 25 months. The columns were operated in a mode as similar as possible to the functioning of the main waterworks with the emphasis on minimizing the washing of the activated carbon layers. Sampling was performed monthly and a total of 222 micropollutants were evaluated. The columns were located at a waterworks in central Bohemia (Czech Republic). Real influent water from the river Jizera after artificial recharge and sand filtration was used. The aim of this study was to verify whether the process of micropollutant removal was suitable under the operating conditions at the waterworks. Clear seasonal patterns of micropollutant concentrations in the influent were detected. All three columns were able to effectively remove or substantially decrease the concentration of most micropollutants. The best performance was shown for the activated carbon Aquasorb 5005, which had the highest surface area and a well developed porous structure with the highest proportion of mesopores. The data were evaluated in order to identify micropollutant parameters important for their removal, and the pH-dependent octanol/water partition coefficient was identified as the key parameter. Other important parameters were charge and polar surface area of the micropollutant molecules.
100 项与 碘普罗胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乳腺疾病 | 美国 | 2023-05-25 | |
| 主动脉疾病 | 美国 | 1995-05-10 | |
| 心血管疾病 | 美国 | 1995-05-10 | |
| 脑血管疾病 | 美国 | 1995-05-10 | |
| 冠状动脉疾病 | 美国 | 1995-05-10 | |
| 外周动脉疾病 | 美国 | 1995-05-10 | |
| 尿道疾病 | 美国 | 1995-05-10 | |
| 造影剂 | 澳大利亚 | 1991-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 132,850 | (Children (<18 years)) | 蓋選鏇憲鏇積獵艱觸鬱(窪夢積鑰齋淵膚簾醖網) = 廠積選鬱襯選範鏇蓋鏇 獵鹽鏇鹹衊鹽築鬱顧窪 (遞繭觸簾艱積觸襯醖壓 ) | - | 2021-12-01 | |
(Elderly (≥65 years)) | 蓋選鏇憲鏇積獵艱觸鬱(窪夢積鑰齋淵膚簾醖網) = 憲糧襯鹹鑰網糧鹹鬱襯 獵鹽鏇鹹衊鹽築鬱顧窪 (遞繭觸簾艱積觸襯醖壓 ) | ||||||
临床4期 | - | 562 | 憲顧獵鹹襯艱糧構襯膚(鬱製廠簾廠鏇構蓋衊膚) = 簾憲鹹遞簾齋鏇襯憲範 鹽艱鹽憲淵範鏇鏇憲顧 (鬱觸觸觸鹽遞齋鹽顧窪 ) 更多 | - | 2012-11-22 | ||
憲顧獵鹹襯艱糧構襯膚(鬱製廠簾廠鏇構蓋衊膚) = 繭獵製積願願糧窪齋醖 鹽艱鹽憲淵範鏇鏇憲顧 (鬱觸觸觸鹽遞齋鹽顧窪 ) 更多 | |||||||
临床3期 | 435 | (Iopromide 370 mg I/mL) | 積鑰鬱鑰糧淵夢憲夢觸 = 構積鑰製顧顧積積築襯 觸積製衊鹽顧憲簾壓膚 (選糧築顧艱鏇遞構艱廠, 積淵齋範淵遞鏇蓋顧繭 ~ 窪繭網獵膚膚製淵積夢) 更多 | - | 2009-07-20 | ||
(Iopromide 300 mg I/mL) | 積鑰鬱鑰糧淵夢憲夢觸 = 蓋獵觸襯壓鬱窪襯願網 觸積製衊鹽顧憲簾壓膚 (選糧築顧艱鏇遞構艱廠, 鑰醖襯鏇鏇範顧積構襯 ~ 繭壓襯簾廠網淵鹽範網) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用